Mya Thomae

Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD.

Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE.

Myraqa is the leading IVD and companion diagnostic consulting firm. Founded in 1998 as a solo practice, Myraqa has grown to include leading experts in Regulatory, Quality, Clinical, Biostatistics and Development. Myraqa serves a wide range of clients, including established diagnostic and therapeutic companies, up & comers and even stealth startups. They work strategically with their customers to smooth the path toward regulatory success. Myraqa has worked on a full range of applications in the US and EU, including PMAs, pre-submissions, IDEs, 510(k)s, de novo 510(k)s, and EU technical files. But Myraqa is more than just a collection of expertise. They''re a team that''s dedicated to helping their clients succeed.

Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA.

Epitope, Inc, operates through its subsidiaries. The company provides and develops diagnostic tests and devices for the detection of Human immunodeficiency virus (HIV) through its subsidiary. The company's products include OraSure, an oral specimen collection device and EPIblot, a serum-based Western blot confirmatory test kit. The prime customers of the company includes life insurance companies, prison systems, the military, and colleges and universities. The products are marketed in United States, Canada, Europe, Asia, Latin America and other countries. It is located in Beaverton, OR.

Illumina Accelerator is a venture capital subsidiary of Illumina, Inc founded in 2014 by Mostafa Ronaghi and Amanda L. Cashin. The firm is headquartered in San Francisco, California.

HX Diagnostics, Inc. provides diagnostic services for infectious diseases. It develops and commercializes seasonal and pandemic influenza assays that allow clinicians to make assessments of their patient's health status. The company was founded in 2006 and is headquartered in San Diego, CA.